O	0	1	[
O	1	8	Effects
O	9	11	of
O	12	13	a
B-intervention	14	22	thoracic
I-intervention	23	36	paravertebral
I-intervention	37	42	block
O	43	45	on
B-condition	46	59	postoperative
I-condition	60	69	analgesia
O	70	72	in
B-eligibility	73	81	patients
I-eligibility	82	92	undergoing
I-eligibility	93	101	modified
I-eligibility	102	109	radical
I-eligibility	110	120	mastectomy
O	120	121	]
O	121	122	.

O	123	132	Following
O	133	143	mastectomy
O	143	144	,
O	145	147	50
O	147	148	%
O	149	151	of
O	152	160	patients
O	161	165	have
O	166	173	chronic
O	174	187	postoperative
O	188	192	pain
O	192	193	.

O	194	201	Studies
O	202	206	have
O	207	212	shown
O	213	217	that
O	218	219	a
O	220	233	paravertebral
O	234	239	block
O	240	242	is
O	243	245	an
O	246	255	effective
O	256	262	method
O	263	265	of
O	266	275	analgesia
O	276	278	as
O	279	283	well
O	284	286	as
O	287	298	anaesthesia
O	298	299	.

O	300	303	The
O	304	307	aim
O	308	310	of
O	311	315	this
O	316	321	study
O	322	324	is
O	325	327	to
O	328	335	compare
O	336	349	postoperative
O	350	354	pain
O	355	361	values
O	362	365	and
O	366	372	opioid
O	373	384	consumption
O	385	390	after
O	391	392	a
O	393	399	single
O	400	404	dose
O	405	407	of
O	408	411	150
O	412	414	mg
O	415	430	levobupivacaine
O	431	435	with
O	436	437	a
O	438	446	thoracic
O	447	460	paravertebral
O	461	466	block
O	467	469	in
O	470	478	patients
O	479	489	undergoing
O	490	500	mastectomy
O	500	501	.

O	502	510	Enrolled
O	511	513	in
O	514	517	the
O	518	523	study
O	524	528	were
B-total-participants	529	534	forty
O	535	543	patients
O	543	544	,
B-age	545	549	aged
I-age	550	552	20
I-age	553	555	to
I-age	556	558	65
O	558	559	,
B-eligibility	560	569	diagnosed
I-eligibility	570	574	with
I-eligibility	575	581	breast
I-eligibility	582	588	cancer
I-eligibility	588	589	,
I-eligibility	590	593	and
I-eligibility	594	604	undergoing
I-eligibility	605	613	modified
I-eligibility	614	621	radical
I-eligibility	622	632	mastectomy
I-eligibility	633	636	and
I-eligibility	637	645	axillary
I-eligibility	646	656	dissection
O	656	657	.

O	658	666	Patients
O	667	671	were
O	672	682	randomized
O	683	687	into
O	688	691	two
O	692	698	groups
O	698	699	,
O	700	702	as
B-control	703	710	control
I-control	711	716	group
O	717	718	(
O	718	723	group
O	724	725	K
O	725	726	,
O	727	728	n
O	728	729	=
B-control-participants	729	731	20
O	731	732	)
O	733	736	and
O	737	745	thoracic
O	746	759	paravertebral
O	760	765	group
O	766	767	(
O	767	772	Group
O	773	774	T
O	774	775	,
O	776	777	n
O	777	778	=
B-intervention-participants	778	780	20
O	780	781	)
O	781	782	.

O	783	796	Postoperative
O	797	801	pain
O	802	808	values
O	809	813	were
O	814	822	recorded
O	823	825	at
O	826	827	0
O	827	828	,
O	829	832	1st
O	832	833	,
O	834	837	6th
O	837	838	,
O	839	843	12th
O	844	847	and
O	848	852	24th
O	853	857	hour
O	858	860	at
O	861	865	rest
O	865	866	,
O	867	872	using
O	873	874	a
O	875	876	0
O	876	877	-
O	877	879	10
O	880	882	mm
O	883	889	Visual
O	890	898	Analogue
O	899	904	Scale
O	905	906	(
O	906	909	VAS
O	909	910	)
O	910	911	.

O	912	922	Additional
O	923	933	quantities
O	934	936	of
O	937	950	postoperative
O	951	959	tramadol
O	960	961	(
O	961	962	1
O	962	963	.
O	963	964	5
O	965	967	mg
O	967	968	/
O	968	970	kg
O	970	971	,
O	972	974	iv
O	975	983	infusion
O	983	984	)
O	985	989	were
O	990	998	recorded
O	998	999	.

O	1000	1015	Postoperatively
O	1015	1016	,
O	1017	1019	at
O	1020	1021	0
O	1021	1022	,
O	1023	1026	1st
O	1026	1027	,
O	1028	1031	6th
O	1031	1032	,
O	1033	1037	12th
O	1038	1041	and
O	1042	1046	24th
O	1047	1051	hour
O	1051	1052	,
O	1053	1061	patients
O	1062	1064	in
O	1065	1068	the
O	1069	1076	control
O	1077	1082	group
O	1083	1086	had
O	1087	1100	significantly
O	1101	1107	higher
B-outcome	1108	1111	VAS
I-outcome	1112	1118	values
O	1119	1123	than
O	1124	1127	the
O	1128	1133	group
O	1134	1141	treated
O	1142	1146	with
O	1147	1148	a
O	1149	1157	thoracic
O	1158	1171	paravertebral
O	1172	1177	block
O	1178	1179	(
O	1179	1180	p
O	1180	1181	<
O	1181	1182	0
O	1182	1183	.
O	1183	1185	01
O	1185	1186	)
O	1186	1187	.

O	1188	1196	Compared
O	1197	1199	to
B-outcome	1200	1203	VAS
I-outcome	1204	1210	scores
I-outcome	1211	1213	at
I-outcome	1214	1227	postoperative
I-outcome	1228	1229	0
I-outcome	1230	1231	h
O	1231	1232	,
O	1233	1238	there
O	1239	1242	was
O	1243	1244	a
O	1245	1258	statistically
O	1259	1270	significant
O	1271	1279	decrease
O	1280	1282	in
O	1283	1286	VAS
O	1287	1293	scores
O	1294	1296	at
O	1297	1300	1st
O	1300	1301	,
O	1302	1305	6th
O	1305	1306	,
O	1307	1311	12th
O	1312	1315	and
O	1316	1320	24th
O	1321	1325	hour
O	1326	1328	in
O	1329	1333	both
O	1334	1340	groups
O	1341	1342	(
O	1342	1343	p
O	1343	1344	<
O	1344	1345	0
O	1345	1346	.
O	1346	1348	01
O	1348	1349	)
O	1349	1350	.

B-outcome	1351	1361	Additional
I-outcome	1362	1365	use
I-outcome	1366	1368	of
I-outcome	1369	1377	tramadol
O	1378	1381	was
O	1382	1395	significantly
O	1396	1401	lower
O	1402	1404	in
O	1405	1410	group
O	1411	1412	T
O	1413	1414	(
O	1414	1415	p
O	1415	1416	<
O	1416	1417	0
O	1417	1418	.
O	1418	1420	01
O	1420	1421	)
O	1421	1422	.

O	1423	1424	A
O	1425	1438	paravertebral
O	1439	1444	block
O	1445	1449	with
O	1450	1451	a
O	1452	1458	single
O	1459	1463	dose
O	1464	1466	of
O	1467	1470	150
O	1471	1473	mg
O	1474	1489	levobupivacaine
O	1490	1496	before
O	1497	1504	general
O	1505	1516	anaesthesia
O	1517	1519	in
O	1520	1528	patients
O	1529	1539	undergoing
O	1540	1548	modified
O	1549	1556	radical
O	1557	1567	mastectomy
O	1568	1571	and
O	1572	1580	axillary
O	1581	1586	lymph
O	1587	1591	node
O	1592	1602	dissection
O	1603	1612	decreases
O	1613	1626	postoperative
O	1627	1631	pain
O	1632	1638	values
O	1639	1642	and
O	1643	1646	the
O	1647	1651	need
O	1652	1655	for
O	1656	1666	analgesics
O	1667	1673	during
O	1674	1677	the
O	1678	1691	postoperative
O	1692	1694	24
O	1695	1700	hours
O	1700	1701	.
